Vraylar (Cariprazine HCl) Patent Expiration, LOE Window & CMS Spending
Vraylar (Cariprazine HCl) by AbbVie: FDA Orange Book core substance LOE 2030-03-17, 0 AB generics, $2.61B 2024 CMS Part D & Medicaid spend, and $1,519 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N204370 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2030-03-17 |
| Last Listed Patent or Exclusivity Date | 2030-03-17 |
| Orange Book Patents (*PED Extensions) | 12 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $2.61B |
| 2024 Medicare Part D Spend | $1.14B |
| 2024 Medicaid Spend | $1.47B |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,519 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.